Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Tosoh Bioscience, a leading name in the research and development services sector, is headquartered in Great Britain and operates extensively across Europe, Asia, and North America. Founded in 2002, the company has established itself as a key player in the biopharmaceutical and life sciences industries, focusing on innovative solutions for analytical and preparative chromatography.
With a diverse portfolio that includes high-performance liquid chromatography (HPLC) columns, mass spectrometry products, and bioseparation technologies, Tosoh Bioscience is renowned for its commitment to quality and precision. The company’s unique offerings cater to a wide range of applications, from drug development to environmental analysis, positioning it as a trusted partner in scientific research. Notable achievements include significant advancements in bioprocessing and a strong reputation for customer support, solidifying its market position as a preferred choice for researchers and laboratories worldwide.
+7 vs industry average
Tosoh Bioscience’s score of 40 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has typical carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
Tosoh Bioscience, a research and development services company based in GB, reported total global carbon emissions for 2024 of approximately 13.6 billion kg CO2e. This includes Scope 1 emissions of approximately 7.3 billion kg CO2e, Scope 2 emissions of approximately 468 million kg CO2e, and Scope 3 emissions of approximately 5.8 billion kg CO2e.
Looking back, Tosoh Bioscience's global emissions in 2023 were approximately 14 billion kg CO2e (Scope 1: ~7.6 billion kg CO2e, Scope 2: ~467 million kg CO2e, Scope 3: ~5.9 billion kg CO2e). In 2022, total global emissions were approximately 15.3 billion kg CO2e (Scope 1: ~7.8 billion kg CO2e, Scope 2: ~518 million kg CO2e, Scope 3: ~7 billion kg CO2e).
Tosoh Bioscience aims to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 30% in fiscal year 2031, compared to fiscal year 2019 levels. Emissions data for Tosoh Bioscience is inherited from its direct parent company, Tosoh Bioscience Limited. CDP data is cascaded from its ultimate parent, Tosoh Corporation.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more